Roche’s Ocrevus set to top $7.6bn in sales by 2028 backed by new dosing approval
On 14 December, the US Food and Drug Administration (FDA) approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab)…
Latest Analysis
-
1 month
-
2 months
-
4 months
-
4 months
-
1 month
-
2 months
-
4 months
-
4 months
Why a surge in PD-1/PD-L1 targeted combination trials is shaping the future of cancer treatment
Targeting programmed cell death protein and its ligand (PD-1/PD-L1) have become the backbone of immunotherapy for cancer. In an era…
Latest Analysis
View More
Covid-19 to shake up site selection decisions
Investors are looking to diversify their global footprint amid the Covid-19 pandemic in an attempt to eliminate concentration risks. However, transforming a company’s operations and…
Covid-19 forces a rethink of global supply chains
As companies across the world are forced to examine the cracks in their supply chains in the wake of the Covid-19 pandemic, they are also…
Coronavirus in India: how the COVID-19 could impact the fast-growing economy
Visit our COVID-19 microsite for the latest coronavirus news, analysis and updates GlobalData's latest Coronavirus Influencers dashboard is now live on…
FDI in a pandemic: How low will the inflows go?
As Covid-19 continues to ravage global economies, there is no doubt foreign direct investment (FDI) will be impacted negatively. The…
Stimulus packages key to recovery from Covid-19 impact, according to leading macroeconomic influencers
As Covid-19 lockdown measures continue across the world, unemployment rates have spiked, and several businesses have collapsed. Stimulus packages are…
Covid-19 lockdown restrictions should be lifted based on the needs of the economy, say leading macroeconomic influencers
The measures being implemented by governments across the world to control the spread of the Covid-19 are having devastating impact…
Latest Content
View More
Coronavirus outbreak: The countries affected
Visit our COVID-19 microsite for the latest coronavirus news, analysis and updates GlobalData's latest Coronavirus Influencers dashboard is now live on…
COVID-19 coronavirus: Top ten most-affected countries
As the coronavirus reaches more than 170 countries and the WHO declares nCoV as a global pandemic, Pharmaceutical Technology lists…
GEMTESA (vibegron) for the Treatment of Overactive Bladder (OAB)
GEMTESA® (vibegron) is the first new oral medication indicated for the treatment of overactive bladder (OAB) with signs of urge…
OpenClinica Featured in ‘In Depth’ Educational TV Series
OpenClinica is pleased to announce that it will be included in public television series In Depth, exhibiting its clinical trials…
ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer
ORGOVYX™ (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate…
EVERSANA and Experic Partner for Life Sciences Industry Manufacturing and Commercialisation
EVERSANA™ and Experic are pleased to announce that they will be partnering to aid life sciences companies in optimising clinical…